Timothy Keutzer Net Worth

The estimated Net Worth of Timothy Keutzer is at least $766 mil dollars as of 27 August 2024. Mr. Keutzer owns over 2,213 units of Spero Therapeutics Inc stock worth over $712,662 and over the last 5 years he sold SPRO stock worth over $53,757. In addition, he makes $0 as Chief Development Officer at Spero Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Keutzer SPRO stock SEC Form 4 insiders trading

Timothy has made over 4 trades of the Spero Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,213 units of SPRO stock worth $2,988 on 27 August 2024.

The largest trade he's ever made was selling 30,971 units of Spero Therapeutics Inc stock on 1 February 2024 worth over $42,121. On average, Timothy trades about 4,804 units every 72 days since 2020. As of 27 August 2024 he still owns at least 531,837 units of Spero Therapeutics Inc stock.

You can see the complete history of Mr. Keutzer stock trades at the bottom of the page.

Timothy Keutzer biography

Timothy Keutzer serves as Chief Development Officer of the Company. He has over 20 years experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining Spero, Mr. Keutzer served in various roles at Cubist Pharmaceuticals, including Vice President of Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr. Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to that role, he also led several of Cubist’s in-licensed development programs, and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes, and includes preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr. Keutzer earned his bachelor’s degree from the University of Kentucky.

How old is Timothy Keutzer?

Timothy Keutzer is 52, he's been the Chief Development Officer of Spero Therapeutics Inc since 2019. There are 12 older and 7 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.

What's Timothy Keutzer's mailing address?

Timothy's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Spero Therapeutics Inc

Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela, eCapital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.

What does Spero Therapeutics Inc do?

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

Complete history of Mr. Keutzer stock trades at Spero Therapeutics Inc

Spero Therapeutics Inc executives and stock owners

Spero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ankit Mahadevia,
  President, Chief Executive Officer, Director
• Dr. Ankit Mahadevia M.D., MBA,
  Co-Founder, CEO, Pres & Director
• Cristina Larkin,
  Chief Operating Officer and Chief Commercial Officer
• David Melnick,
  Cheif Medical Officer
• Dr. David A. Melnick M.D.,
  Chief Medical Officer
• Cristina Larkin,
  Chief Operating Officer
• Thomas Parr,
  Chief Scientific Officer
• Cynthia Smith,
  Independent Director
• Milind Deshpande,
  Independent Chairman of the Board
• Frank Thomas,
  Independent Director
• Patrick Vink,
  Independent Director
• John Pottage,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Sharon Klahre,
  IR Contact Officer
• Scott Jackson,
  Independent Director
• Timothy Keutzer,
  Chief Development Officer
• Stephen DiPalma,
  Chief Financial Officer, Treasurer
• Timothy Keutzer,
  Chief Devel. Officer
• James P. Brady,
  Chief Human Resource Officer
• David Musselman,
  Sr. VP of Sales & Market Access
• Tamara Lynn Joseph L.L.M., J.D.,
  Chief Legal Officer
• Ted Jenkins,
  VP & Head of Investor Relations
• Dr. Thomas R. Parr Jr., Ph.D.,
  Chief Scientific Officer
• Satyavrat Shukla C.F.A.,
  Chief Financial Officer
• David P Southwell,
  Director
• John J Gorman,
  Director
• Jack Fingerhut,
  President
• Allen S Greene,
  Chairman of the Board and CEO
• Lager H Martin,
  Director
• Joel Sendek,
  Chief Financial Officer
• Plc Gsk,
  10% owner
• Joseph R Fish,
  EVP & Chief Technology Officer
• Leonard J Stanley,
  Director
• Vikas Goyal,
  Director
• Casper Breum,
  Director
• Stanley P Wirtheim,
  Chief Financial Officer
• Zohar Ben Dov,
  10% owner
• Esther Rajavelu,
  See Remarks
• Capital Management, Llc Aqu...,
  
• Kathleen Tregoning,
  
• Kamal Hamed,
  Chief Medical Officer
• Sath Shukla,
  CEO & President
• Tamara L Joseph,
  Chief Legal Officer